About 15% of colon cancers are dMMR, which confers resistance to chemotherapy. ICIs have FDA approval for metastatic dMMR ...

Nxera and Lilly entered the multi-target collaboration in 2022 to leverage Nxera’s GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and ...

Eli Lilly's gene-silencing drug lepodisiran has ... inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.